Supernus Resubmits NDA to FDA for Apomorphine Infusion Device to Treat Parkinson's
By Stephen Nakrosis
Supernus Pharmaceuticals resubmitted a new drug application to the Food and Drug Administration for its apomorphine infusion device to treat patients with Parkinson's disease.
The SPN-830 apomorphine infusion device is designed for the continuous treatment of motor fluctuations in Parkinson's disease.
In October 2022, Supernus said it received a complete response letter from the FDA indicating the company's NDA wouldn't be approved in its then-current form. At the time, Supernus said the FDA was seeking additional information and analysis, but didn't request additional efficacy or clinical studies.
The company also said "the FDA mentioned at the time that approval of the NDA required inspections that could not be completed in a timely manner due to Covid-19 travel restrictions."
Supernus said it believes it addressed the FDA's questions related to the complete response letter and will continue to work with the agency as it reviews the SPN-830 NDA.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 09, 2023 17:30 ET (21:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: AI Leaders Excel in Earnings Season
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth